We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$177M
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter
Est. Return
+31.91%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$158M
AUM Growth
+$48.6M
(+44%)
Cap. Flow
+$17.3M
Cap. Flow
% of AUM
10.96%
Top 10 Holdings %
Top 10 Hldgs %
69.15%
Holding
41
New
16
Increased
13
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$6.03M |
| 2 |
Royalty Pharma
RPRX
|
+$5.87M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$5.12M |
| 4 |
Zevra Therapeutics
ZVRA
|
+$4.75M |
| 5 |
UroGen Pharma
URGN
|
+$4.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$19.5M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$9.84M |
| 3 |
Evolus
EOLS
|
+$4.02M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
+$1.71M |
| 5 |
XOMA
Xoma
XOMA
|
+$1.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.94% |
| 2 | Miscellaneous | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$2.15B
| $37.4M | 23.62% |
1,870,000
| – | – |
|
|
2
Evolus
EOLS
$598M
| $22.2M | 14.02% |
1,369,821
-287,790
| -17% | -$4.02M |
|
|
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $13.8M | 8.71% |
478,659
-6,341
| -1% | -$173K |
|
|
4
Jazz Pharmaceuticals
JAZZ
$16.1B
| $6.13M | 3.87% |
+55,000
| New | +$6.03M |
|
|
5
Royalty Pharma
RPRX
$28.4B
| $6M | 3.79% |
+212,000
| New | +$5.87M |
|
|
XOMA
6
DELISTED
Xoma
XOMA
| $5.17M | 3.26% |
195,096
-55,033
| -22% | -$1.49M |
|
7
Rigel Pharmaceuticals
RIGL
$906M
| $5M | 3.16% |
309,100
+4,100
| +1% | +$48.2K |
|
|
8
Zevra Therapeutics
ZVRA
$745M
| $4.86M | 3.07% |
+700,000
| New | +$4.75M |
|
9
Anika Therapeutics
ANIK
$281M
| $4.68M | 2.95% |
189,308
+23,911
| +14% | +$620K |
|
|
RVNC
10
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.26M | 2.69% |
820,000
-1,980,000
| -71% | -$9.84M |
|
|
11
Ironwood Pharmaceuticals
IRWD
$709M
| $4.12M | 2.6% |
1,000,000
+951,988
| +1,983% | +$5.12M |
|
12
Verastem
VSTM
$723M
| $3.92M | 2.48% |
+1,310,287
| New | +$3.56M |
|
|
OPTN
13
DELISTED
OptiNose
OPTN
| $3.81M | 2.41% |
379,239
+222,572
| +142% | +$3.25M |
|
|
14
UroGen Pharma
URGN
$2.19B
| $3.56M | 2.25% |
+280,345
| New | +$4.16M |
|
|
SCPH
15
DELISTED
scPharmaceuticals
SCPH
| $3.55M | 2.24% |
778,874
+357,171
| +85% | +$1.73M |
|
16
Establishment Labs
ESTA
$2.15B
| $3.25M | 2.05% |
+75,000
| New | +$3.26M |
|
17
Acadia Pharmaceuticals
ACAD
$4.8B
| $3.03M | 1.91% |
196,895
+191,895
| +3,838% | +$3.2M |
|
|
DAWN
18
DELISTED
Day One Biopharmaceuticals
DAWN
| $2.87M | 1.81% |
+205,675
| New | +$2.93M |
|
19
Aclaris Therapeutics
ACRS
$876M
| $2.83M | 1.79% |
2,458,873
+531,427
| +28% | +$652K |
|
20
TELA Bio
TELA
$35.1M
| $2.81M | 1.77% |
1,110,000
+484,355
| +77% | +$1.72M |
|
21
Indivior Pharmaceuticals
INDV
$4.11B
| $2.63M | 1.66% |
+270,000
| New | +$3.16M |
|
22
Exagen
XGN
$183M
| $1.65M | 1.04% |
534,398
+175,701
| +49% | +$455K |
|
23
Milestone Pharmaceuticals
MIST
$151M
| $1.52M | 0.96% |
999,790
-239,409
| -19% | -$348K |
|
24
Surrozen
SRZN
$265M
| $1.32M | 0.83% |
110,000
+43,916
| +66% | +$388K |
|
25
AYTU BioPharma
AYTU
$24.5M
| $1.18M | 0.74% |
500,958
+28,489
| +6% | +$73.8K |
|
Similar funds
RP
MSA
HF
BFAG
CWP
MVM
CMP
JESC
Stonepine Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Stonepine Capital Management held 41 positions worth $158M, up 44% from $110M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Stonepine Capital Management deployed $17.3M of net new capital in Q3 2024, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 55,000 shares worth $6.13M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Revance Therapeutics, Inc., an estimated $9.84M trimmed.
- Stonepine Capital Management's largest Q3 2024 buy was Jazz Pharmaceuticals: 55,000 shares worth $6.13M.
- Stonepine Capital Management added most to Ironwood Pharmaceuticals in Q3 2024, an estimated $5.12M increase.
- Stonepine Capital Management's biggest Q3 2024 reduction was Revance Therapeutics, Inc., cutting an estimated $9.84M.
- Stonepine Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $19.5M.
- Stonepine Capital Management's ten largest holdings make up 69% of its $158M portfolio in Q3 2024.
- Stonepine Capital Management opened 16 new positions and closed 3 in Q3 2024.
- Stonepine Capital Management's portfolio value rose 44% quarter-over-quarter to $158M.
Based on Stonepine Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.